FibroBiologics Completes Master Cell Bank with Charles River for Upcoming Clinical Trials

• FibroBiologics has completed its proprietary master cell bank in partnership with Charles River Laboratories to support upcoming clinical trials.

• The cGMP-compliant bank will facilitate the development of CYWC628, a fibroblast-based therapy targeting diabetic foot ulcers.

FibroBiologics, Inc. has completed its proprietary master cell bank in collaboration with Charles River Laboratories. The bank, manufactured under FDA Good Manufacturing Practices (cGMP), has passed all required safety testing and will support upcoming clinical trials.

FibroBiologics, a clinical-stage biotechnology company with more than 160 patents issued and pending, is focused on developing fibroblast-based therapies for chronic diseases. The company is investigating treatments for conditions such as multiple sclerosis, degenerative disc disease, psoriasis, cancer, and human longevity.

A key focus is CYWC628, a fibroblast-based therapy targeting diabetic foot ulcers, a condition with limited long-term treatment options. Charles River’s cGMP manufacturing facilities will produce the CYWC628 cell banks and drug product for an upcoming phase I/II clinical trial scheduled to begin later this year.

“Completing our master cell bank for CYWC628 is a defining moment in our work to advance fibroblast-based cell therapies,” said Pete O’Heeron, CEO of FibroBiologics. “With this foundation in place, we are progressing on our path to the clinic in 2025 and strengthening our ability to collaborate with research and clinical partners worldwide.”

Kerstin Dolph, Corporate Senior Vice President, Global Manufacturing at Charles River, added, “The completion of their master cell bank marks a significant milestone in their program and highlights the power of scientific collaboration.”